Search the Newsreel

Aktis Oncology (AKTS) posts Q2 2026 results with $517M cash runway into 2029

Aktis Oncology reported its Q2 2026 results, highlighting progress in its targeted radiopharmaceutical pipeline with promising early data for AKY-2519 and ongoing trials for AKY-1189. The company maintains a strong financial position with $517.3 million in cash, cash equivalents, and marketable securities, projected to …

Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026

Aktis Oncology reported its financial results and business highlights for the second quarter of 2026, showcasing strong execution and progress in its clinical pipeline. The company presented promising first-in-human clinical imaging and dosimetry data for AKY-2519 and is actively enrolling patients in Phase 1b …

Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Aktis Oncology (NASDAQ:AKTS) has received a consensus "Moderate Buy" rating from eight analysts, with an average 12-month price target of $34.60. The company reported quarterly revenue of $3.23 million, surpassing estimates, though its loss per share slightly missed expectations. Insider trading activity included a …

Aktis Oncology (AKTS) Expected to Release Earnings on Monday

Is Aktis Oncology (AKTS) Fairly Valued After Its Recent Pullback?

Aktis Oncology (AKTS) stock has experienced a recent pullback, dropping 4% in the past week and 17% in the last month, despite year-to-date gains. The company, which focuses on radiopharmaceutical research, trades at a Price-to-Book (P/B) ratio of 2.6x, slightly above the US Biotech …

Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value?

Aktis Oncology (AKTS) stock has recently fallen by 16.3%, but current valuations still lean towards expensive rather than undervalued, passing only 2 of 6 valuation tests. The company's P/B ratio of 2.6x is in line with the biotech industry average, suggesting it's roughly fairly …

AKTIS ONCOLOGY INC : LEERINK PARTNERS ASSUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $33

Leerink Partners has initiated coverage on AKTIS Oncology Inc. with an Outperform rating. The firm has set a target price of $33 for the company's stock. This news comes from Reuters and reflects an analyst's opinion on the company's future performance.

Aktis Oncology (NASDAQ:AKTS) Stock Passes Above 50 Day Moving Average - Here's Why

Aktis Oncology director Ken Herrmann sells $119,274 in stock

Ken Herrmann, a director at Aktis Oncology (NASDAQ:AKTS), sold 4,856 shares of common stock for $119,274 on July 20, 2026. Prior to this sale, Herrmann acquired the same shares through vested stock options for $2,858. The company's stock has seen a nearly 10% increase …

Aktis Oncology director Ken Herrmann disposes of common shares worth $119,256.78

Aktis Oncology director Ken Herrmann sold 4,856 common shares on July 20, 2026, at $24.56 per share, totaling $119,256.78. He had acquired these shares previously through option exercises at much lower prices. Following these transactions, his direct common stock holding fell to zero, though …

Aktis Oncology (AKTS) director sells 4,856 shares after exercising options

Aktis Oncology director Ken Herrmann exercised options for 4,856 shares at various strike prices and subsequently sold all those shares for approximately $119,000 gross proceeds. The transactions, which involved both execution of options and sale of common stock, were completed on July 20, 2026, …

Aktis Oncology, Inc. (AKTS) director sells 3,065 post-exercise

Ken Herrmann, a director at Aktis Oncology, Inc. (AKTS), executed a same-day option exercise and sale. He exercised 3,065 stock options at $0.08 per share and immediately sold these 3,065 shares at a weighted average price of $25.2067. After the transaction, Herrmann retains 3,506 …

Enterprise value to revenue forward of Aktis Oncology, Inc. – NASDAQ:AKTS

This article provides "Enterprise value to revenue forward" data for Aktis Oncology, Inc. (NASDAQ: AKTS) on TradingView. The content indicates a period, a value, and change percentages, noting that the data was "Made by humans."

Form 144 AKTIS ONCOLOGY For: 17 July By Investing.com

This article from Investing.com reports on a Form 144 filing for Aktis Oncology, specifically for July 17. The content provided is minimal, essentially just stating the filing and date without furnishing any details about the filing itself. The majority of the page consists of …

[144] Aktis Oncology, Inc. SEC Filing

This article reports on an SEC Form 144 filing by Aktis Oncology, Inc. (AKTS) detailing a proposed sale of securities. The filing indicates a stock option exercise by an individual, with 3065 shares of common stock valued at $77,258.54 to be sold through Morgan …

AKTS Options Volatility — NASDAQ:AKTS

This article provides an overview of Aktis Oncology, Inc. (AKTS) options volatility on TradingView. It highlights implied volatility curves and at-the-money (ATM) implied volatility across different expirations, offering tools for traders to assess market expectations and identify potential trading opportunities for AKTS. The content …

Price to sales forward of Aktis Oncology, Inc. – NASDAQ:AKTS

This page from TradingView provides financial information for Aktis Oncology, Inc. (NASDAQ: AKTS), specifically focusing on its forward price-to-sales ratio. It lists the company's financial data, news, and community sentiment within the platform's interface. The article itself does not contain analytical content but rather …

Aktis Oncology (AKTS) Gains 2.8% as Biotech Sentiment Improves - Volatility Smile

Aktis Oncology, Inc. Actuals & Estimates (NASDAQ:AKTS)

Aktis stock gains Strong Buy from Raymond James (AKTS:NASDAQ)

Should I buy Aktis Oncology, Inc. (AKTS)

AKTIS ONCOLOGY (AKTS) Stock Price, News & Analysis

Aktis Oncology (AKTS) Earnings Date and Reports 2026 $AKTS

Aktis Oncology (AKTS) Stock Price, News & Analysis $AKTS